Literature DB >> 8569980

Plasma cytokine levels in hemolytic uremic syndrome.

N C van de Kar1, R W Sauerwein, P N Demacker, G E Grau, V W van Hinsbergh, L A Monnens.   

Abstract

The cytokines tumor necrosis factor-alpha (TNF-alpha) and its soluble TNF receptors 55 and 75 (sTNFR55, sTNFR75), interleukin-1 beta (IL-1BETA) and interleukin-6 (IL-6) were measured in plasma from 13 patients with the hemolytic uremic syndrome (HUS) on admission. No significant changes in the plasma levels of TNF-alpha and IL-1beta were detected in the HUS patients as compared to the plasma levels of the control groups. Levels of IL-6 were significantly elevated in the plasma of those HUS patients who had external manifestations, consisting of seizures, loss of consciousness, coma and pancreatic necrosis. Although the exact function of IL-6 in the plasma of HUS patients is still unknown and the group of HUS patients is small, plasma IL-6 is associated with the the severity and outcome of the disease. Plasma levels of sTNR55 and sTNFR75 were significantly elevated in all HUS patients compared to the healthy controls, but they were also elevated in the children with chronic renal failure. This indicates that elevated levels of circulating sTNFR should be carefully interpreted when kidney failure exists.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8569980     DOI: 10.1159/000188737

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  9 in total

Review 1.  Advances in haemolytic uraemic syndrome.

Authors:  C M Taylor; L A Monnens
Journal:  Arch Dis Child       Date:  1998-02       Impact factor: 3.791

2.  Cytokines in haemolytic uraemic syndrome associated with verocytotoxin-producing Escherichia coli infection.

Authors:  C D Inward; M Varagunam; D Adu; D V Milford; C M Taylor
Journal:  Arch Dis Child       Date:  1997-08       Impact factor: 3.791

3.  Serum ferritin as an indicator of the development of encephalopathy in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome.

Authors:  Masaki Shimizu; Natsumi Inoue; Mondo Kuroda; Hitoshi Irabu; Maiko Takakura; Hisashi Kaneda; Naotoshi Sugimoto; Kazuhide Ohta; Akihiro Yachie
Journal:  Clin Exp Nephrol       Date:  2017-03-10       Impact factor: 2.801

Review 4.  Diarrheagenic Escherichia coli.

Authors:  J P Nataro; J B Kaper
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

5.  Administration of ricin induces a severe inflammatory response via nonredundant stimulation of ERK, JNK, and P38 MAPK and provides a mouse model of hemolytic uremic syndrome.

Authors:  Veselina Korcheva; John Wong; Christopher Corless; Mihail Iordanov; Bruce Magun
Journal:  Am J Pathol       Date:  2005-01       Impact factor: 4.307

6.  Synergistic interactions between interferon-gamma and TRAIL modulate c-FLIP in endothelial cells, mediating their lineage-specific sensitivity to thrombotic thrombocytopenic purpura plasma-associated apoptosis.

Authors:  Radu Stefanescu; Dustin Bassett; Rozbeh Modarresi; Francisco Santiago; Mohamad Fakruddin; Jeffrey Laurence
Journal:  Blood       Date:  2008-03-13       Impact factor: 22.113

7.  Angiopoietin-1 and -2 as markers for disease severity in hemolytic uremic syndrome induced by enterohemorrhagic Escherichia coli.

Authors:  Masaki Shimizu; Natsumi Inoue; Mondo Kuroda; Mao Mizuta; Naotoshi Sugimoto; Hisashi Kaneda; Kazuhide Ohta; Akihiro Yachie
Journal:  Clin Exp Nephrol       Date:  2016-03-05       Impact factor: 2.801

8.  p38 mitogen-activated protein kinase mediates lipopolysaccharide and tumor necrosis factor alpha induction of shiga toxin 2 sensitivity in human umbilical vein endothelial cells.

Authors:  Matthew K Stone; Glynis L Kolling; Matthew H Lindner; Tom G Obrig
Journal:  Infect Immun       Date:  2007-12-17       Impact factor: 3.441

9.  Chemokine expression in human astrocytes in response to shiga toxin 2.

Authors:  Naomi Kioka; Koichi Minami; Akira Tamura; Norishige Yoshikawa
Journal:  Int J Inflam       Date:  2012-12-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.